Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alfacell Corporation has entered into a distribution agreement with BL&H for the commercialization of Onconase in South Korea, Taiwan and Hong Kong. Onconase is currently being evaluated as a treatment for unresectable malignant mesothelioma in a confirmatory Phase IIIb clinical trial.
Subscribe to our email newsletter
Under the terms of the agreement, Alfacell has granted BL&H exclusive rights in the defined territory for the marketing, sales and distribution of Onconase (ranpirnase). Alfacell has received an upfront fee of $100,000 and is eligible for milestone payments based on the achievement of certain regulatory approvals and net sales levels. Alfacell will also receive 50% of all net sales in the territory.
In addition, Alfacell will manufacture and supply the product to BL&H, while BL&H will be responsible for all activities and costs related to regulatory filings and commercial activities in the territory.